Fundraising Fox

Peytant

Plymouth, US · Founded 2019 · Minnesota corporation · 12 employees on LinkedIn · 1 known investors

Peytant develops amnion-derived membrane coverings using human placental tissue to reduce the body's foreign body response in implants used for luminal disease treatment. The company's products are designed to increase patency and help clinicians manage vascular and other luminal conditions.

Founders & leadership

Peytant was founded in 2019 by John Schorgl and Steve Healy.

JSJohn Schorgl
John SchorglFounder & Executive Chairman
SHSteve Healy
Steve HealyFounder & Director
JN
James NessExecutive

Board

JC
Jeffrey ChambersBoard director
BFBruce Faulken
Bruce FaulkenBoard director
CWCraig Walker
Craig WalkerBoard director
CAClay Anselmo
Clay AnselmoBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$4.9M disclosed across 4 rounds · 2015–2023

$2.9MraisedJan 2025 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John SchorglExecutive Officer, Director, Promoter
  • Bruce FaulkenDirector
  • Craig WalkerDirector
  • Steven HealyDirector
  • Clay AnselmoDirector
Offering amount
$5M
Amount sold
$2.9M
First sale
Feb 2023
Incorporated
Corporation, Minnesota
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$275KraisedMar 2021 · 3 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • John SchorglExecutive Officer
  • Steven J. HealyDirector
  • Craig WalkerDirector
  • Jeffrey ChambersDirector
  • Bruce FaulkenDirector
  • Clay AnselmoDirector
Offering amount
$2M
Amount sold
$275K
Minimum investment
$3
Proceeds to insiders
$150K
First sale
Mar 2021
Incorporated
Corporation, Minnesota
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$1.2MraisedOct 2017 · 11 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Steven HealyDirector
  • John SchorglExecutive Officer, Director
  • Clay AnselmoDirector
  • Jeffrey ChambersDirector
  • Bruce FaulkenDirector
Offering amount
$4M
Amount sold
$1.2M
First sale
Jul 2017
Incorporated
Corporation, Minnesota
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$576.5KraisedSep 2015 · 8 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • James NessExecutive Officer
  • Jeffrey ChambersDirector
  • John SchorglExecutive Officer, Director
Offering amount
$3M
Amount sold
$576.5K
Sales commissions
$14.4K
Placement agents
Dougherty & Company LLC
First sale
Aug 2015
Incorporated
Corporation, Minnesota
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Companies competing with Peytant for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Frequently asked questions

What does Peytant do?
Peytant develops amnion-derived membrane coverings using human placental tissue to reduce the body's foreign body response in implants used for luminal disease treatment. The company's products are designed to increase patency and help clinicians manage vascular and other luminal conditions.
Who founded Peytant?
Peytant was founded by John Schorgl, Steve Healy in 2019.
Who are Peytant's investors?
Peytant's investors include Relevance Ventures.
How much funding has Peytant raised?
Peytant has disclosed $4.9M raised across 4 rounds.
Where is Peytant headquartered?
Peytant is headquartered in Plymouth, US.